Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
2
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
alder biopharmaceutical
allergan
american academy of neurology
atogepant
biohaven
biotech
bob azelby
botox
boulder/denver blog main
boulder/denver top stories
brian abrahams
calcitonin gene-related peptide
cholesterol
data
detroit blog main
detroit top stories
drugs
eli lilly
eptinezumab
erenumab
fda
fremanezumab
galcanezumab
impel neuropharma
inclisiran
indiana blog main
indiana top stories
jefferies
lasmiditan
What
big
2
×
drug
year
aces
announced
approval
arguments
ceo
cholesterol
class
commercialized
companies
competitors
decades
drugs
fda
flexible
inclisiran
key
lowering
make
meant
medco
medicine
medicines
meeting
migraine
nasdaq
neuro
new
open
oral
passed
potential
pricing
taken
test
therapies
twice
week
Language
unset
Current search:
amgen
×
big
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
